News
03-01-2010, 10:41 PM
Celsion Corporation today announced that it will initiate a Randomized Phase II Study of Lyso-Thermosensitive Liposomal Doxorubicin (ThermoDox®) and Radiofrequency Ablation (RFA) for Colorectal Liver Metastases (CRLM). Dr. Steven K. Libutti, Professor and Vice Chairman, Department of Surgery and Director of the Montefiore-Einstein Center for Cancer Care and Albert Einstein College of Medicine in New York City, will serve as Principal Investigator for the study.
More... (http://www.news-medical.net/news/20100302/Celsion-to-commence-Phase-II-Study-of-ThermoDox-and-RFA-for-CRLM.aspx)
More... (http://www.news-medical.net/news/20100302/Celsion-to-commence-Phase-II-Study-of-ThermoDox-and-RFA-for-CRLM.aspx)